Normal pregnancy is associated with decreased uterine vascular contraction and increased blood flow even though angiotensin II (AngII) levels are increased. AngII not only activates the angiotensin type 1 receptor (AT 1 R) to mediate vasoconstriction but also angiotensin type 2 receptor (AT 2 R) to cause vasodilation. We hypothesized that upregulation of AT 2 R expression and function accounts for increased uterine artery blood flow during pregnancy. Virgin, pregnant (at different days of gestation) and post-partum Sprague-Dawley rats were used to determine uterine artery hemodynamics using micro ultrasound and plasma angiotensin II levels by ELISA. Isolated uterine arteries were examined for AT 1 R and AT 2 R expression and isometric contraction/relaxation. Plasma AngII levels were steady up to mid-pregnancy, increased as pregnancy advanced, reaching a peak in late pregnancy, and then restored to pre-pregnant levels after delivery. The pattern of increase in AngII levels mirrored a parallel increase in uterine blood flow. AT 1 R expression did not change, but AT 2 R expression increased during pregnancy correlating with uterine blood flow increase. Treatment with the AT 2 R antagonist PD123319 reduced uterine arterial blood flow. Vasoconstriction to angiotensin II was blunted in pregnant rats. Treatment with PD123319 caused greater enhancement of AngII contraction in pregnant than virgin rats. Ex vivo exposure of estradiol to uterine arterial rings dose dependently upregulated AT 2 R expression, that was inhibited by estrogen receptor antagonist. These results demonstrate that elevated AngII levels during gestation induce an increase in uterine blood flow via heightened AT 2 R-mediated signaling. Estrogens appear to directly upregulate uterine vascular AT 2 R independent of any endogenous factors.
Introduction
Fetal growth and development require a progressive increase in maternal uteroplacental circulation. These adjustments in uteroplacental blood flow are achieved by vasodilatation and remodeling of the uterine arteries [1] [2] [3] . Thus, during pregnancy, the uterine artery diameter significantly increases and uterine artery resistance decreases [1] [2] [3] [4] . Failure to make or sustain these changes during pregnancy is associated with high incidence of clinical complications such as intrauterine growth restriction, preeclampsia, and fetal loss [5] [6] [7] [8] .
The mechanisms mediating uteroplacental changes during pregnancy are not fully understood. However, the renin-angiotensin system (RAS) appears to play a central role in both normal pregnancies and in preeclampsia [9] [10] [11] . The RAS affects both structure and function-related processes in the uteroplacental and the systemic circulations. Angiotensin II (Ang II), the main effector peptide of the RAS, is a potent vasoconstrictor. During normotensive pregnancy, circulating Ang II levels are increased [10] , yet pregnant women have reduced vascular resistance and enhanced vasodilation. This paradoxical vascular effect has been attributed to the relative nonreactivity of the pregnant uterine arteries to Ang II [12, 13] . Studies have shown that Ang II not only activates the angiotensin type 1 receptor (AT 1 R) to mediate vasoconstriction but also angiotensin type 2 receptor (AT 2 R) to cause vasodilation [14] [15] [16] [17] . Although the role of the AT 1 R in vascular contraction and hypertension is well characterized [18] [19] [20] , the role of the AT 2 R in uterine blood flow regulation, particularly during pregnancy, is not clearly understood. A few studies have suggested a possible role of AT 2 R in the regulation of uterine vascular function during pregnancy. One study in sheep showed that the amount of AT 2 R in the uterine arteries were greater than in nonpregnant sheep [21] . These AT 2 Rs are shown to mediate enhanced vasodilation in uterine arteries of rat, mice, and sheep during normal pregnancy [22] [23] [24] .
The absence of a blunted pressor response to Ang II with associated reduced blood flow [25] and increased pulsatility in the uterine artery [26] are among the few predictors of susceptibility for pre-eclampsia, underscoring the importance of the RAS in this still poorly understood disease. It is possible that the decreased AT 2 R expression that is observed in preeclamptic pregnancies [27] and hypertensive pregnant rats [28, 29] may contribute for these compromised uteroplacental adaptations. Also, genetic polymorphism of AT 2 R is shown to be associated with the increased risk of preeclampsia [30, 31] . Although these circumstantial evidences implicate the importance of AT 2 R in the regulation of vascular function, little is known about the functional role of AT 2 R in regulating uterine blood flow and its adaptation to pregnancy. Given that pregnancy increases AT 2 R-dependent vasodilatation in isolated rat aortae [32] and treatment with an AT 2 R blocker abolishes the normal pregnancy associated fall in systemic blood pressure in mice [33] and this fall in blood pressure is absent in mice lacking the expression of AT 2 R [34], we considered that AT 2 R-mediated vasodilatation might also be an important contributor to the pregnancy-associated increase in uterine arterial blood flow. Thus, in the present study, we tested the hypothesis that upregulation of AT 2 R expression and function accounts for increased uterine artery blood flow during pregnancy. To test this hypothesis, we measured temporal changes in plasma Ang II levels, its receptor expression, and uterine arterial blood flow during pregnancy, and determined if AT 2 R contributes to increased uterine arterial blood flow. Given the findings that estradiol plays an important role in increasing uterine arterial blood flow [35] [36] [37] [38] , we further tested the hypothesis that estradiol upregulates AT 2 R expression in uterine arteries.
Methods

Animals
All procedures were in accordance with National Institutes of Health guidelines (NIH Publication No. 85-23, revised 1996) with approval by the Institutional Animal Care and Use Committee at the University of Wisconsin at Madison. Virgin and timed-pregnant SpragueDawley rats (Charles River, Wilmington, MA, positive plug = day 1) were used in the experiments. Rats were housed in polypropylene cages in a temperature and humidity-controlled environment. Animal housing facilities were controlled on a 12-h light, 12-h dark cycle and rats were given free access to standard laboratory chow and water. Twelve-week-old virgin, pregnant [at early (day 6), mid (day 14), and late (days 18, 20, and 21) gestation) and post-partum (day 4 after delivery)] rats (n = 6 at each time point) were subjected for micro-ultrasound between 9 and 10 AM to assess uterine artery hemodynamics; then euthanized by CO 2 asphyxiation and blood was collected for Ang II measurements, and uterine arteries were isolated for RNA and protein expression. A portion of uterine arteries at gestational day 20 was used for vascular reactivity and ex vivo estradiol incubations.
Ang II enzyme immunoassay
Blood was collected and plasma was separated. An Ang II enzyme immunoassay kit (Phoenix Pharmaceutical Inc, Burlingame, CA) was used to measure plasma Ang II concentrations [39] with a detection range of 0.08-1.55 ng/mL. Intra-and interassay variations were 5%-10% and <15%, respectively. A total of 50 μL of plasma in duplicate was used for this assay. All procedures were conducted according to the assay kit instructions.
Uterine artery blood flow
In nonpregnant, pregnant, and post-partum rats, pulsed-wave Doppler ultrasonography (Vevo 2100 Imaging System; FUJIFILM VisualSonics Inc. Toronto, Ontario, Canada) was performed to evaluate blood flow in the uterine artery, similar to procedures that have been described previously [40] . In brief, rats were anesthetized with 3% isoflurane and were maintained at 1.5%. Rats were placed in dorsal recumbency on a heated monitoring platform (FUJIFILM VisualSonics Inc.), which allowed monitoring of heart rate, electrocardiogram traces, respiration rate, and body temperature. Fur was clipped from the abdomen, and a depilatory agent was used to remove any remaining fur. Doppler ultrasonography was performed using a 30-MHz transducer (FUJIFILM VisualSonics Inc.). All measurements and analyses were performed using Vevo LAB software (v.1.7, FUJIFILM VisualSonics Inc.) by researchers who were blinded to the experimental groups. The angle between the ultrasound probe and the direction of the flow was kept at less than 50
• (33 • on average) during the recordings of the velocity waveforms. The velocities of the main uterine arteries were recorded below the bladder and at the level where the main uterine artery branches from the internal iliac artery. Peak systolic velocity (PSV) and end diastolic velocity (EDV), the area under the peak velocity-time curve, and R-R interval were measured from three consecutive cardiac cycles and the results were averaged. Mean velocity (MV) over the cardiac cycle was calculated by dividing the area under the peak velocity-time curve by the R-R interval. Blood flow velocity distribution was determined using the following formula: were calculated to quantify the pulsatility of blood velocity waveforms. A set of pregnant rats at gestation day 20 were given AT 2 R antagonist PD123319 or vehicle (n = 6 each), and after 30 min, changes in uterine arterial hemodynamics were recorded as described above. PD123319 (Sigma, St. Louis, MO), dissolved in 0.9% w/v saline, was administered as a bolus dose of 1 mg/kg followed by continuous intravenous infusion at 1 mg/kg/h using a microsyringe pump (New Era Pump System Inc., Farmingdale, NY). This dose of PD123319 was similar to previous studies [41, 42] , and it was selected based on report that PD123319 is highly selective for AT 2 R at doses less than 1000 μg/kg/min [43] .
RNA isolation and quantitative real-time PCR
Total RNA was isolated from uterine arteries using TRIzol reagent (Invitrogen, Carlsbad, CA). All RNA isolates were made DNA free by treatment with DNase and further purification with RNeasy Clean Up Kit (QIAGEN Inc, Valencia, CA). Total RNA concentration and purity were determined using an ND-1000 Nanodrop spectrophotometer (Thermo Fisher Scientific, Newark, DE). Two micrograms of total RNA were reverse transcribed using a modified Maloney murine leukemia virus-derived reverse transcriptase (New England Biolabs Inc, Ipswich, MA) and a blend of oligo (dT) and random hexamer primers (Invitrogen, Grand Island, NY). The reaction was carried out at 28
• C for 15 min, then 42
• C for 50 min, and stopped by heating at 94
• C for 5 min followed by 4
• C before storage at -20
• C until further analysis. The mRNA levels of AT 1a R, AT 1b R, and AT 2 R were quantified by using the CFX96 real-time thermal cycler (Bio-Rad, Hercules, CA). The specific TaqMan Primers for AT 1a R, AT 1b R, AT 2 R, and GAPDH were from Applied Biosystems (Carlsbad, CA). PCR conditions were 2 min at 50
• C and 10 min at 95
• C for 1 cycle, then 15 s at 95
• C and 1 min at 60
• C for 50 cycles.
Results were calculated using the 2 -CT method and expressed in fold change of the gene of interest relative to nonpregnant controls. All reactions were performed in duplicate, and GAPDH was used as an internal control.
Western blotting
Uterine arteries of nonpregnant and day 20 pregnant rats were homogenized in ice-cold RIPA buffer (Cell Signaling Technology, Danvers, MA) containing a protease inhibitor tablet (Roche, Indianapolis, IN) and phosphatase inhibitor cocktail-2 and -3 (Sigma). Tissue lysates were centrifuged (14,000 g for 10 min at 4
• C), and the protein content was measured by using the Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL). The supernatant was resuspended in the NuPAGE LDS sample buffer and reducing agent (Invitrogen). Proteins (30 μg) alongside of Precision Plus Standard (Kaleidoscope, Bio-Rad) were resolved on 4% to 12% gradient NuPAGE Bis-Tris Gels (Invitrogen) at 100 V for 2 hours at room temperature and then transferred onto Immobilon-P membranes (Millipore Inc, Billerica, MA) at 100 V for 1.5 hours. The membranes were blocked with 5% bovine serum albumin for 1 hour and then incubated overnight at 4
• C with primary antibodies. The primary antibodies were AT 1 R (mouse monoclonal, sc-57036, 1:500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), AT 2 R (rabbit monoclonal, ab92445, 1:1000; Abcam, Cambridge, MA) and β-actin (rabbit monoclonal, #4070, 1:5000; Cell Signaling Technologies). After washing, the membranes were incubated with secondary antibodies (anti-rabbit or -mouse conjugated with horseradish peroxidase) and detected with the Pierce ECL detection kits (Thermo Scientific, Waltham, MA). The densitometric measurement was done using Image J software. Results were normalized and expressed as ratios of the intensity of a specific band to that of β-actin.
Ex vivo vascular reactivity studies
Uterine arteries were placed directly into ice-cold Krebs buffer (in mM: NaCl, 119; KCl, 4.7; CaCl 2 , 2.5; MgSO 4 , 1.17; NaHCO 3 , 25; KH 2 PO 4 , 1.18; EDTA, 0.026; and d-glucose, 5.5; pH 7.4). Arteries were cut into 1.5 mm segments, and two 25 μm wires were inserted through the lumen. One wire was attached to a stationary support driven by a micrometer, while the other was attached to an isometric force transducer (Multi Myograph, Model 610M Danish Myo Technologies, Aarhus, Denmark). The myograph organ bath (6 mL) was filled with Krebs buffer maintained at 37
• C and aerated with 95% O 2 -5% CO 2 . The vessels were washed and incubated for 30 min under zero force before performing the normalization procedure. Arterial segments were normalized to 0.7 of L 13.3 kPa using the normalization software (Powerlab, ADInstruments, Colorado Springs, CO), which has been found previously to be optimal for active tension development in this vessel [44, 45] . After obtaining the optimal tension, the vessels were allowed to equilibrate for 1 h and then the presence of intact endothelium was confirmed by observing the relaxation response to 1 μM acetylcholine (Sigma) in rings precontracted with 1 μM phenylephrine (Sigma), as described previously [29] . Then, vascular contractile responses to cumulative additions of Ang II (10 −11 to 3 × 10 −8 M, Sigma) were determined.
To assess the effects of Ang II receptors (AT 1 R and AT 2 R), cumulative dose-response curves were constructed to Ang II in the absence or after 30 min incubation with either losartan (10 −5 M, Sigma) or PD 123319 (10 −5 M). Since tachyphylaxis develops to repeated Ang II cumulative dose-response curves, only one dose-response curve was obtained per tissue [44] .
Estradiol treatment
Isolated uterine arteries from day 20 pregnant rats were cut into small rings and incubated in phenol red free DMEM (Gibco Laboratories; Thermo Scientific) (with 5% charcoal stripped serum, Sigma) containing increasing concentrations of E 2 (24 h, 0.1-100 nM, Sigma) in absence or presence of ER antagonist ICI 182, 780 (1 μM, Sigma) as in previous studies [46, 47] . Then the uterine arteries were processed for AT 2 R mRNA and protein expression as described above.
Statistical analysis
All data are expressed as the mean ± standard error of the mean (SEM). Statistical significance was determined with one-way analysis of variance followed by the Bonferroni post hoc test. Comparisons between the two groups were performed using Student t tests. Differences were considered statistically significant at a value of P < 0.05. Statistical analysis was conducted using GraphPad Prism (GraphPad, San Diego, CA).
Results
Plasma Ang II levels and uteroplacental blood flow Plasma Ang II levels were steady up to mid-pregnancy (day 14) and then increased as pregnancy advanced, reaching a peak in late pregnancy (day 20) with a 300% maximal increase compared to Figure 1 . Temporal changes in plasma Ang II levels across pregnancy. Plasma Ang II levels were higher during late pregnancy. Plasma from nonpregnant (NP), pregnant, and post-partum (PP) rats was determined by enzyme immunoassay. n = 6 in each * P < 0.05 vs NP.
pre-pregnant levels. In post-partum (after 4 days of delivery), Ang II levels recovered to pre-pregnancy values ( Figure 1 ; n = 6 at each time point; P < 0.05). A similar pattern was observed for the uterine arterial blood flow with a significant increase starting at gestation day 18 and reaching an approximately fourfold increase in late gestation and restoring to pre-pregnant levels after delivery (Figure 2A ; n = 6; P < 0.05). The uterine artery resistance and pulsatility index showed an opposite trend with decreased indices from day 18 to day 20 of gestation and then restoring to pre-pregnant levels after delivery ( Figure 2B , and C; n = 6; P < 0.05).
Changes in AT 1 and AT 2 receptors in the uterine artery
At the mRNA level, rodents possess two AT 1 receptor isoforms, designated AT 1a R and AT 1b R. There was no significant change in expression of both AT 1 R isoforms in uterine artery across gestation ( Figure 3A ; n = 6). AT 2 R mRNA expression was not altered until day 14 pregnancy but a significant difference started at gestation day 18 and reached an approximately sixfold increase in late gestation. At post-partum day 4, AT 2 R mRNA levels returned to pre-pregnancy levels ( Figure 3B ; n = 6 at each time point; P < 0.05). As shown in Figure 3C , western blotting showed that AT 1 R protein levels were unchanged and AT 2 R were significantly increased in the late pregnant rats compared to nonpregnant uterine arteries (n = 5 in each, P < 0.05).
Effect of AT 2 R blockade on uterine blood flow PD123319 treatment significantly reduced uterine arterial blood flow by 40% at day 20 of gestation ( Figure 4A ; n = 6; P < 0.05). PD123319 treatment also significantly increased RI ( Figure 4B ; n = 6; P < 0.05) and PI ( Figure 4C ; n = 6; P < 0.05). Thus, these results indicate that PD123319 treatment decreases uterine artery blood flow and increases uterine vascular resistance.
Ex vivo vasomotor responses
Ang II-induced contractile responses in endothelium-intact uterine arteries of late pregnant rats were significantly lower with a rightward shift in the dose-response curves as well as a decrease in maximal responses than in uterine arteries of nonpregnant rats (Figure 5A and B, n = 6; P < 0.05). Pretreatment of the uterine arterial rings with losartan completely blocked Ang II-induced contractions (Figure 5A and B; n = 6; P < 0.05). On the other hand, pretreatment with PD123319 significantly enhanced Ang II-induced contractions in uterine arteries from late pregnant rats ( Figure 5B , n = 6; P < 0.05) but had no significant effect in nonpregnant uterine arteries ( Figure 5A , n = 6). PD123319 did not significantly alter Ang II-induced contractions in endothelium-denuded arteries from late pregnant rats ( Figure 5C , n = 6).
Effect of estradiol on the expression of AT 2 R in uterine arteries
Since pregnancy increases estradiol, which is known to play a role in vascular adaptations and increases in uterine blood flow [35] [36] [37] [38] , we next determined the regulatory effect of estradiol on AT 2 R expression. Uterine arteries of pregnant rat were treated ex vivo with estradiol for 24 h, which significantly increased AT 2 R mRNA ( Figure 6A ; n = 5; P < 0.05) and protein abundance ( Figure 6B ; n = 5; P < 0.05). Importantly, inhibition of estradiol receptors with ICI 182,780 abolished estradiol-induced upregulation of AT 2 R mRNA (n = 6) and protein (n = 5) (Figure 6A and B; P < 0.05), suggesting a direct effect of estradiol on AT 2 R expression in uterine arteries in an estradiol receptor-dependent manner. Quantitative RT-PCR analysis of temporal mRNA levels of (A) AT1R (both AT1aR and AT1bR) and (B) AT2R normalized to GAPDH in nonpregnant (NP), pregnant (P), and post-partum (PP) rats. (C) Representative western blots for AT1R and AT2R and β-actin are shown at top; blot density obtained from densitometric scanning of Ang II receptors normalized to β-actin is shown at bottom. n = 5-6 each, * P < 0.05 vs NP.
Discussion
The uterine artery undergoes significant vasodilatation and remodeling during gestation, resulting in increased blood flow and supply of nutrients and oxygen to the developing fetus [3, 48] . Here, we present several lines of evidence that the Ang II and its AT 2 R contribute to pregnancy-dependent increases in uterine artery blood flow in rats. First, we show that pregnancy leads to a temporal increase circulating Ang II levels and uterine arterial AT 2 R mRNA transcripts with little or no change in AT 1 R mRNA transcripts relating to the onset and magnitude of uterine arterial blood flow in rats. Second, acute blockade of AT 2 R with PD123319 decreased uterine arterial blood flow in pregnant rats, suggesting the underlying importance of RAS, and specifically AT 2 R, in the uteroplacental function. Third, the increased AT 2 R expression in the uterine arteries blunted vascular contractile responses to Ang II. Finally, estrogen has a direct role in increasing AT 2 R expression in uterine arteries. Therefore, we suggest that increases in vascular AT 2 R and Ang II stimulated responses may mediate the onset and maintenance of uterine blood flow during pregnancy. RAS plays an important role in the regulation of vascular function and remodeling [49] . Renin enzymatically cleaves angiotensinogen to angiotensin I (Ang I), and then Ang I is cleaved by angiotensinconverting enzyme to the biologically functional Ang II, which is central to the pathway of the RAS. Activation of RAS, with high concentrations of circulating Ang II, has been repeatedly demonstrated during normal human pregnancy [50] [51] [52] [53] [54] [55] . To our knowledge, this is the first study that determined ontogenic changes in plasma Ang II levels in rat dams. We show that the plasma concentration of Ang II in a nonpregnant rat is 200 pg/mL and increases by threefold to 600 pg/mL during the late pregnancy. These Ang II concentrations in pregnant rats are similar to that observed in pregnant women, which is threefold higher in third trimester compared with nonpregnant women (60 pg/mL vs 20 pg/mL, respectively) [51, 53, 56] .
Importantly, the increase in plasma Ang II levels mirrored a parallel increase in blood flow with proportional decrease in uterine arterial resistance. This is intriguing given that Ang II is a potent vasoconstrictor and previous studies have found that experimental increase in circulating Ang II levels lead to decreased blood flow in renal and mesenteric circulation in nonpregnant state [57] . The reason for these differences is that in nonpregnant state Ang II mediates most of its effects through its major vasoconstrictive AT 1 R, as there are very little or no vasodilatory AT 2 R in nonpregnant vasculature [58] . In the present study, we examined the expression patterns of Ang II receptors across pregnancy and demonstrated that both AT 1 R and AT 2 R receptor subtypes are present in abundance in the uterine arteries. However, pregnancy did not induce changes in AT 1 R (both AT 1a R and AT 1b R) but selectively increased the expression of AT 2 R with the upregulation observed as early as day 18 and more pronounced increase at late gestation. Thus, it appears that pregnancy induces upregulation of AT 2 R allowing it to emerge as a predominant receptor in the uterine arteries and Ang II may mediate most of its effect through this receptor. In support of this notion, a previous study in sheep that used receptor binding assays showed that pregnancy increased uterine artery AT 2 R density, where it comprises the majority of total Ang II receptors [59] . Thus, this study demonstrates that pregnancy causes a reprogramming of the Ang II receptor expression pattern, resulting in ontogenic increase in uterine arterial AT 2 R levels that coincides with Ang II increase and relates to the onset and magnitude of uterine blood flow increase in pregnant rats.
In this study, in vivo administration of PD123319 reduced the pregnancy-induced increase in uterine arterial blood flow in late pregnant rats suggesting that AT 2 R activation contributes, in part, to the increase in uterine blood flow in pregnant rats. In vivo administration of PD123319 can also act by blocking AT 2 R's expressed in the heart and kidneys [60, 61] . To dissect out the direct contribution of AT 2 R to uterine blood flow, we examined vascular reactivity to Ang II in ex vivo isolated uterine arteries. In the present study, Ang IIinduced contractile responses were significantly blunted in pregnant rats compared to nonpregnant rats. The ED 50 and E max were reduced in the pregnant than nonpregnant rats correlating with the increase in AT 2 R expression and decrease in RI. The findings that PD123319 significantly increased Ang II-induced contractions in uterine arteries of pregnant rats and that its blockade abrogated the difference in the Ang II-induced contractions between nonpregnant and pregnant uterine arteries indicate that pregnancy-induced attenuation in uterine arterial contractions to Ang II is conferred primarily by enhanced AT 2 R activity. Other studies in uterine arteries have also reported blunted vasomotor responses to Ang II in pregnant mice [23] , sheep [21] , and rat [22] , Because we find that PD123319 opposed Ang II-induced contractions only in the presence of functional endothelium, we suggest the blunted arterial sensitivity to Ang II primarily occurred due to functional AT 2 R-mediated endothelial effects. Consistently, studies have shown that AT 2 R are present in the endothelium and activates nitric oxide, endothelium-derived hyperpolarizing factor, and prostacyclin vasodilatory pathways [62] [63] [64] [65] . These findings support the notion that the heightened AT 2 R activity is a predominant mechanism in maintaining uteroplacental blood flow in pregnancy. It is also important to note that AT 2 R also plays an important role in other vascular beds like cerebral circulation [66, 67] , where AT 2 R is the only angiotensin receptor [68] . Although, in this study we focused on vascular contraction/relaxation, it is also possible that AT 2 R participates in gestational vascular remodeling [69, 70] and this needs to be evaluated in further studies. The question arises as to how pregnancy provokes increase in AT 2 R expression. It has been reported that the amount of vascular AT 2 R is greater in female compared with male spontaneously hypertensive rats, possibly due to an effect of estrogen on AT 2 R expression [71] . Additionally, estrogens are also shown to play an important role in mediating the gestational increase in uterine artery blood flow [35] [36] [37] [38] . Because AT 2 R-mediated responses are upregulated in the presence of estrogen, and because estrogen increases substantially during pregnancy, we reasoned that AT 2 R-mediated vascular responses are possibly upregulated during pregnancy due to increased expression/activity of vascular AT 2 R. The finding that ex vivo estradiol exposure in uterine arteries upregulates AT 2 R mRNA suggests that AT 2 R is a physiological target for estradiol and that estrogens can directly regulate the transcription of AT 2 R independent of any endogenous factors. This is consistent with the finding that estradiol upregulates AT 2 R in the kidneys [72, 73] and myometrium [74] . Possible mechanisms include modulation of AT 2 R transcription through estrogen response elements [75] . Although the AT 2 R promoter does not contain estrogen response elements [76] , estrogen may activate AT 2 R transcription from alternative response elements such as the activator protein site (AP-1) [77, 78] . Intriguingly, estradiol does not upregulate AT 2 R expression in the lungs [79] and urinary bladder [80] . Why estradiol selectively regulates AT 2 R expression in certain tissues but not others remain to be clarified.
In conclusion, temporal alterations in circulating Ang II levels and vascular AT 2 R signaling appear to correlate with the progression and magnitude of uterine artery blood flow in pregnant rats. Estrogens appear to directly upregulate uterine vascular AT 2 R independent of any endogenous factors. This suggests that local uterine vascular RAS, in addition to central RAS, may play an important role in maintenance of blood flow to the uteroplacental unit. Since studies show that AT 2 R expression is decreased in preeclampsia [81] [82] [83] [84] , further studies should examine whether the compromised vascular function and reduced uterine artery blood flow in preeclampsia is related to decreased vascular AT 2 R expression, and if this receptor could be activated for therapeutic advantage.
